1. Home
  2. ESPR vs MIN Comparison

ESPR vs MIN Comparison

Compare ESPR & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.14

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Logo MFS Intermediate Income Trust

MIN

MFS Intermediate Income Trust

HOLD

Current Price

$2.44

Market Cap

284.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
MIN
Founded
2008
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
731.9M
284.5M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESPR
MIN
Price
$3.14
$2.44
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.75
N/A
AVG Volume (30 Days)
17.1M
241.5K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
7.31%
EPS Growth
60.71
N/A
EPS
N/A
0.08
Revenue
$403,135,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.81
N/A
P/E Ratio
N/A
$30.50
Revenue Growth
21.31
N/A
52 Week Low
$0.76
$2.41
52 Week High
$4.18
$2.72

Technical Indicators

Market Signals
Indicator
ESPR
MIN
Relative Strength Index (RSI) 70.95 44.18
Support Level $2.37 N/A
Resistance Level $3.15 $2.52
Average True Range (ATR) 0.02 0.02
MACD 0.03 -0.00
Stochastic Oscillator 43.75 25.00

Price Performance

Historical Comparison
ESPR
MIN

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

About MIN MFS Intermediate Income Trust

MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.

Share on Social Networks: